Since both the B-cell receptor and WNT/PCP pathways regulate the migration and proliferation of CLL cells, and the BTK inhibitor ibrutinib can only block signals from the B-cell receptor, it was reasonable to therapeutically pair ibrutinib with anti-ROR1 mAb. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.